**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 47295

**Manuscript Type:** MINIREVIEWS

**Imaging biomarkers for the treatment of esophageal cancer**

Hayano K *et al*. Imaging biomarker for esophageal cancer

Koichi Hayano, Gaku Ohira, Atsushi Hirata, Tomoyoshi Aoyagi, Shunsuke Imanishi, Toru Tochigi, Toshiharu Hanaoka, Kiyohiko Shuto, Hisahiro Matsubara

**Koichi Hayano, Gaku Ohira, Atsushi Hirata, Tomoyoshi Aoyagi, Shunsuke Imanishi, Toru Tochigi, Toshiharu Hanaoka, Hisahiro Matsubara,** Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 260-8677, Japan

**Kiyohiko Shuto,** Department of Surgery, Teikyo University Medical Center, Chiba 299-0111, Japan

**ORCID number:** Koichi Hayano (0000-0003-4733-8220); Gaku Ohira (0000-0001-7246-5390); Atsushi Hirata (0000-0001-5931-7596); Tomoyoshi Aoyagi (0000-0001-5280-3751); Shunsuke Imanishi (0000-0001-7534-210X); Toru Tochigi (0000-0002-8734-3975); Toshiharu Hanaoka (0000-0001-9106-3442); Kiyohiko Shuto (0000-0001-7265-8117); Hisahiro Matsubara (0000-0002-2335-4704).

**Author contributions**: Hayano K contributed to conception and design; all authors contributed to manuscript writing and preparing figures; all authors reviewed and approved this article to be published.

**Conflict-of-interest statement:** We confirm that there are no known conflicts of interest associated with this publication, and there has been no significant financial support for this work that may have influence on the contents.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Koichi Hayano,** **FACS, MD, PhD, Associate Professor, Doctor,** Department of Frontier Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. hayatin1973@yahoo.co.jp

**Telephone:** +81-43-2262110

**Fax:** +81-43-2262113

**Received:** March 14, 2019

**Peer-review started:** March 14, 2019

**First decision:** April 30, 2019

**Revised:** May 7, 2019

**Accepted:** May 31, 2019

**Article in press:**

**Published online:**

**Abstract**

Esophageal cancer is known as one of the malignant cancers with poor prognosis. To improve the outcome, combined multimodality treatment is attempted. On the other hand, advances in genomics and other ‘omic’ technologies are paving way to the patient-oriented treatment called “personalized” or “precision” medicine. Recent advancements of imaging techniques such as functional imaging make it possible to use imaging features as biomarker for diagnosis, treatment response, and prognosis in cancer treatment. In this review, we will discuss how we can use imaging derived tumor features as biomarker for the treatment of esophageal cancer.

**Key words:** Esophageal cancer; Computed tomography perfusion; Dynamic-contrast-enhanced magnetic resonance imaging; Texture analysis; Diffusion-weighted imaging; Positron emission tomography

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Advances in imaging techniques enable us to assess tumor biology such as viability, vascular physiology, heterogeneity, or metabolism, which can be new approaches to investigate biomarker for cancer treatment. In this review, we will discuss various functional imaging techniques including computed tomography/magnetic resonance perfusion, texture analysis, diffusion-weighted imaging, and positron emission tomography in terms of prediction of treatment response or prognosis in esophageal cancer.

Hayano K, Ohira G, Hirata A, Aoyagi T, Imanishi S, Tochigi T, Hanaoka T, Shuto K, Matsubara H. Imaging biomarkers for the treatment of esophageal cancer. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Esophageal cancer is the seventh most common cancer, and sixth leading cause of death in the world[1]. Surgical resection is the only curative method for esophageal cancer, but is limited to early stage disease, and the recurrence rate after radical resection of esophageal cancer is reported to be approximately 50%, and most cases of recurrence occur within two years after surgery[2-4].

In this context, personalized or precision medicine, which enables the best choice of treatment based on certain biomarkers, is highly desirable, preventing side-effect and extra expenses, leading to more effective multidisciplinary treatments. Angiogenesis, tumor stroma, hypoxia, heterogeneity, and metabolism are known as typical biological features of malignancies, and these have been investigated to be biomarkers for diagnosis, prognosis, and treatment response. These biological features are usually investigated by the cell and molecular biology, but recent advances in imaging technique enable non-invasive assessment of various tumor functions, which have been investigated their biomarker value in malignancies. Imaging derived markers have the advantage of being non-invasive, spatially resolved and repeatable, compared to bio-specimen biomarkers which are obtained by removing a sample from a patient. Recent increasing interests in “Radiomics”, which is an emerging field that converts imaging data into a high dimensional mineable feature space using a large number of automatically extracted data-characterization algorithms, makes imaging derived biomarkers more valuable. In these contexts, this review will discuss how we can use various imaging derived biomarkers including perfusion analysis using computed tomography (CT) or magnetic resonance imaging (MRI), texture analysis, diffusion-weighted imaging (DWI), and positron emission tomography (PET) in terms of prediction of treatment response or prognosis to improve outcome of esophageal cancer patients.

**PERFUSION ANALYSIS**

Perfusion analysis using dynamic contrast-enhanced CT (DCE-CT/CT perfusion) and DCE-MRI (MR perfusion) can quantify tissue hemodynamics by measuring the temporal changes in tissue attenuation after administration of intravenous contrast media[5-7]. Since “angiogenesis” plays an important role in almost all types of cancer progression[8-10], quantification of vascular physiology using CT or MR perfusion techniques may reflect tumor angiogenesis, and has a potential to be a biomarker in cancer treatment[11]. These perfusion techniques are readily incorporated into the existing CT and MRI protocol, and enables *in vivo* quantification of tissue hemodynamics using the modeling tracer kinetics on the imaging workstation (Figure 1)[5,6]. In esophageal cancer, several previous papers reported associations of CT or MR perfusion parameters with treatment response to chemotherapy or chemoradiotherapy (Table 1). In MR perfusion studies, it was reported that higher Ktrans value (a parameter related to vessel permeability and tissue blood flow) before chemoradiation therapy (CRT) was associated with better treatment response[12,13]. In CT perfusion studies, Hayano *et al*[14] reported that higher blood flow of the tumor before CRT was associated with better treatment response and overall survival in esophageal squamous cell carcinoma patients. Makari *et al*[15] also reported that high tumor BF measure by CT perfusion might predict good response to neoadjuvant chemotherapy and CRT. Interestingly, all these reports suggested that a higher blood flow/perfusion of the tumor was associated with a better outcome of CRT or chemotherapy. It is reasonable because a higher tumor blood flow/perfusion leads to a better drug delivery and a higher oxygenation, resulting in better chemo- and radio-sensitivity. There are a few paper reporting perfusion change in esophageal cancer during chemotherapy or CRT. Sun *et al*[12] demonstrated that the complete response group showed a significant decrease in Ktrans. Similarly, Hayano *et al*[16] reported that a significant decrease of blood flow in the tumor was observed from CT perfusion study of esophageal cancer, and they reported that patients with a greater reduction in tumor blood flow during CRT survived significantly longer than those with lower tumor blood flow reduction. It is speculated that the tissue fibrosis due to CRT leads to compression of tumor capillaries and increased flow resistance, results in decrease of blood flow/perfusion after CRT. In fact, it was reported that patients who achieved pathological complete response (pCR) after neoadjuvant CRT had tumors with lower blood flow than non-pCR[17].

Regarding relationship between CT/MR perfusion and angiogenesis, published results are controversial. For example, Chen *et al*[18] demonstrated that tumor blood volume measured by CT perfusion was significantly correlated with micro-vessel density in esophageal cancer, while Sato *et al*[19] reported that there was no significant correlation of tumor blood flow with the micro-vessel density in CT perfusion study of gastric cancer. Sato *et al*[19] speculated that blood flow assessed with perfusion imaging reflected only the functional vessels with a lumen, and not the functionless tumor vascularity; and therefore, micro-vessel density studied immunohistochemically *in vitro* using surgical specimens might be inadequate for “*in vivo* tumor vascular physiology. These factors may affect controversial results on relationship of CT/MR perfusion with immunohistochemically evaluated angiogenesis.

This perfusion technique using CT and MRI is very interesting and exciting technique with a potential to be a useful biomarker, but this technique is still considered a research tool in the realm of oncology. A consensus and standardization of data acquisition and analysis methods have yet to be established. The definition of the tumor region of interest (ROI) is subject to similar consideration, because the method used to draw the ROI clearly influences the perfusion parameters. Relatively high radiation dose and complicated procedure should be improved to be more common examination in clinical practice of esophageal cancer.

**TEXTURE ANALYSIS**

Analysis of texture within tumor on medical imaging such as CT, MRI, and PET, which reflects structural abnormality or heterogeneity in the tumor, is emerging as a potential biomarker to predict prognosis and treatment response in patients with cancer[20], because most malignant tumors show a striking amount of intratumor heterogeneity, which has implications for diagnosis, treatment efficacy, and the identification of drug targets[21]. There are various methods including statistical-, model-, and transform-based methods with various texture parameters[22]. Common texture parameters are entropy (a measure of irregularity), uniformity (a measure of uniform distribution of grey-levels), skewness (a measure of asymmetry of the histogram), kurtosis (a measure of peakedness and tailedness), and fractal dimension (a measure of complexity)[23-25]. Ganeshan *et al*[26] reported that tumor heterogeneity (uniformity) assessed on unenhanced CT was correlated with 18F-fluorodeoxyglucose (18F-FDG) uptake, and was an independent predictor of survival in 21 patients with esophageal cancers. Yip *et al*[27] reported that post-treatment uniformity and entropy of the tumor measured on contrast-enhanced CT were correlated with overall survival in esophageal cancer patients treated with CRT. In fractal analysis of PET imaging, Tochigi *et al*[28] reported that the low fractal dimension of tumor 18F-FDG uptake was associated with favorable survival, and they concluded that metabolic heterogeneity measured by fractal analysis can be a novel imaging biomarker for survival in patients with esophageal squamous cell carcinoma.

These texture analysis is a post-processing mathematical technique, which can apply to any medical imaging with no additional radiation exposure, special protocol, and cost, and maximizes the information obtained from current standard medical imaging (Figure 2). This technique still needs further investigation and standardization to be used in clinical practice, but has a potential to be a valuable clinical tool in the management of esophageal cancer.

**DIFFUSION-WEIGHTED IMAGING**

In 1905, Einstein described molecular diffusion or Brownian motion formally on the basis of the random translational motion of molecules[29]. Recent advances in magnetic resonance gradient technology have allowed acquisition of the apparent diffusion coefficient (ADC) value, which can be calculated by the DWI measurements acquired with a different gradient duration and amplitude (b-values)[30]. DWI has been discussed in terms of its biomarker value for cancer treatment in a consensus meeting, and a publication on consensus and recommendations for DWI as a cancer biomarker has been published highlighting the potential of this technique in the management of cancer patients (Figure 3)[31].

In esophageal cancer, there are seven papers evaluating DWI for prediction of CRT response and prognosis[32], but the results are controversial (Table 2). In 2011, Aoyagi *et al*[33] reported that higher baseline tumor ADC was associated with better survival. Another study also suggested that high baseline tumor ADC was associated with good response to CRT[34] , while De Cobelli *et al*[35] reported that the high baseline tumor ADC was associated with poor response to CRT. Because of these conflicting results, it is still unclear whether pre-therapeutic tumor ADC can really predict response or survival after CRT. Cheng *et al*[32] performed meta-analysis, and reported that change of ADC and post-therapeutic ADC of the tumor were promising reliable and valuable predictor for the response to CRT, rather than pre-therapeutic ADC. Interestingly, Imanishi *et al*[36] reported that early increase of tumor ADC (> 15% after 20 Gy) could predict treatment response with 85% of accuracy and 100% of positive predictive value. Similarly, three studies suggested importance of post-CRT ADC and the change of ADC after 2-3weeks of CRT in terms of prediction of response to CRT in esophageal cancer[37-39].

Because DWI does not need radiation exposure and contrast agents, it can be an ideal biomarker. However, standardization of data acquisition and analysis methods have yet to be established for DWI. Low spatial resolution, especially in high b-value image, should be improved for accurate detection and quantification of the tumor.

**POSITRON-EMISSION TOMOGRAPHY**

PET is a quantitative imaging technique with use of various types of tracers. 18F-FDG, which can quantify glucose metabolism of the tissue, is the most common clinical PET tracer. Theoretically, malignant tumor cells exhibit strongly enhanced energy consumption, and lead to increased 18F-FDG uptake due to the increased number of glucose transporters and the increased hexokinase activity (Figure 4). The standardized uptake value (SUV) is generally used to quantify the tissue glucose metabolism, which has been reported its biomarker value in the treatment response and prognosis in various types of malignancies.

Regarding the biomarker value of pre-therapeutic PET in surgically treated esophageal cancer, Fukunaga *et al*[40] reported that a high SUV of the tumor before surgery had a poorer prognosis compared with those with low FDG uptake in esophageal cancer patients who received curative surgery without neoadjuvant therapy in 1998. After this paper had been published, seven papers on this subject were published[41-47], and all those papers suggested that high tumor SUV before surgery was associated with poor survival in surgically treated esophageal cancer (no neoadjuvant therapy)[48]. On the other hand, interestingly, pretherapeutic tumor SUV may not associate with survival in patients who received neoadjuvant chemotherapy or CRT[49,50], while the tumor SUV after neoadjuvant therapy can be a biomarker for survival. Swisher et al. reported that the tumor SUV after CRT is the most accurate test to predict survival in esophageal cancer patients (87% is adenocarcinoma) who were treated CRT followed by curative surgery[51]. Higuchi *et al*[52] also demonstrated that post-CRT SUV uptake in the tumor (cut-off 2.5) was the preoperative prognostic factor in esophageal squamous cell carcinoma patients who were treated neoadjuvant CRT or chemotherapy. Regarding change in tumor SUV during neoadjuvant therapy, early decrease (after 2 wk of neoadjuvant therapy) in FDG uptake is reported to be a predictive marker for response and survival[53-59]. However, some studies included patients with a wide range of disease (adenocarcinomas and squamous cell carcinomas, stage I through IV), and studies used different neoadjuvant treatment regimens.

Nevertheless, FDG-PET seems to be served as a useful biomarker for treatment response and prognosis in various types of treatments, and we need further investigation with a large multicenter prospective trial to confirm usefulness of FDG-PET in the management of esophageal cancer.

**CONCLUSION**

Ideal biomarker should be simple, non-invasive, reproducible, and widely available. Given the wide availability and the less invasiveness, imaging has a big potential to be an ideal biomarker. As we reviewed, various imaging biomarkers showed interesting results, and some of them are ready to use in clinical practice of esophageal cancer patients, which would provide patients more personalized and effective treatment, leading better outcome.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Su XD**, Zhang DK, Zhang X, Lin P, Long H, Rong TH. Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma. *J Thorac Dis* 2014; **6**: 949-957 [PMID: 25093092 DOI: 10.3978/j.issn.2072-1439.2014.07.14]

3 **Chen G**, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. *World J Surg* 2007; **31**: 1107-1114 [PMID: 17426905 DOI: 10.1007/s00268-006-0551-1]

4 **Nakagawa S**, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. *J Am Coll Surg* 2004; **198**: 205-211 [PMID: 14759776 DOI: 10.1016/j.jamcollsurg.2003.10.005]

5 **Axel L**. Cerebral blood flow determination by rapid-sequence computed tomography: Theoretical analysis. *Radiology* 1980; **137**: 679-686 [PMID: 7003648 DOI: 10.1148/radiology.137.3.7003648]

6 **Miles KA**, Hayball M, Dixon AK. Colour perfusion imaging: A new application of computed tomography. *Lancet* 1991; **337**: 643-645 [PMID: 1671994 DOI: 10.1016/0140-6736(91)92455-B]

7 **Padhani AR**. Functional MRI for anticancer therapy assessment. *Eur J Cancer* 2002; **38**: 2116-2127 [PMID: 12387837 DOI: 10.1016/s0959-8049(02)00388-x]

8 **Des Guetz G**, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. *Br J Cancer* 2006; **94**: 1823-1832 [PMID: 16773076 DOI: 10.1038/sj.bjc.6603176]

9 **Carmeliet P**, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 2000; **407**: 249-257 [PMID: 11001068 DOI: 10.1038/35025220]

10 **Jain RK**, Carmeliet P. SnapShot: Tumor angiogenesis. *Cell* 2012; **149**: 1408-1408.e1 [PMID: 22682256 DOI: 10.1016/j.cell.2012.05.025]

11 **Miles KA**. Perfusion CT for the assessment of tumour vascularity: Which protocol? *Br J Radiol* 2003; **76 Spec No 1**: S36-S42 [PMID: 15456712 DOI: 10.1259/bjr/18486642]

12 **Sun NN**, Liu C, Ge XL, Wang J. Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. *Diagn Interv Radiol* 2018; **24**: 195-202 [PMID: 30091709 DOI: 10.5152/dir.2018.17369]

13 **Lei J**, Han Q, Zhu S, Shi D, Dou S, Su Z, Xu X. Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging. *Oncol Lett* 2015; **10**: 3607-3612 [PMID: 26788177 DOI: 10.3892/ol.2015.3779]

14 **Hayano K**, Okazumi S, Shuto K, Matsubara H, Shimada H, Nabeya Y, Kazama T, Yanagawa N, Ochiai T. Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: Initial clinical results. *Oncol Rep* 2007; **18**: 901-908 [PMID: 17786353 DOI: 10.3892/or.18.4.901]

15 **Makari Y**, Yasuda T, Doki Y, Miyata H, Fujiwara Y, Takiguchi S, Matsuyama J, Yamasaki M, Hirao T, Koyama MK, Nakamuara H, Monden M. Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. *J Surg Oncol* 2007; **96**: 220-229 [PMID: 17450532 DOI: 10.1002/jso.20820]

16 **Hayano K,** Shuto K, Satoh A,Aoyagi T, Narushima K, Gunji H, Kono T, Yanagawa N, Okazumi S, Matsubara H. Tumor blood flow change measured by CT perfusion during chemoradiation therapy (CRT) for monitoring response and predicting survival in patients with esophageal cancer. *Esophagus* 2014; **11**: 72-79 [DOI: 10.1007/s10388-013-0400-x]

17 **Djuric-Stefanovic A**, Micev M, Stojanovic-Rundic S, Pesko P, Saranovic Dj. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade. *Eur J Radiol* 2015; **84**: 2477-2484 [PMID: 26467704 DOI: 10.1016/j.ejrad.2015.09.025]

18 **Chen TW**, Yang ZG, Wang QL, Li Y, Qian LL, Chen HJ. Whole tumour quantitative measurement of first-pass perfusion of oesophageal squamous cell carcinoma using 64-row multidetector computed tomography: Correlation with microvessel density. *Eur J Radiol* 2011; **79**: 218-223 [PMID: 20399055 DOI: 10.1016/j.ejrad.2010.03.024]

19 **Satoh A**, Shuto K, Okazumi S, Ohira G, Natsume T, Hayano K, Narushima K, Saito H, Ohta T, Nabeya Y, Yanagawa N, Matsubara H. Role of perfusion CT in assessing tumor blood flow and malignancy level of gastric cancer. *Dig Surg* 2010; **27**: 253-260 [PMID: 20668380 DOI: 10.1159/000288703]

20 **Ganeshan B**, Miles KA. Quantifying tumour heterogeneity with CT. *Cancer Imaging* 2013; **13**: 140-149 [PMID: 23545171 DOI: 10.1102/1470-7330.2013.0015]

21 **Durrett R**, Foo J, Leder K, Mayberry J, Michor F. Intratumor heterogeneity in evolutionary models of tumor progression. *Genetics* 2011; **188**: 461-477 [PMID: 21406679 DOI: 10.1534/genetics.110.125724]

22 **Davnall F**, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, Ganeshan B, Miles KA, Cook GJ, Goh V. Assessment of tumor heterogeneity: An emerging imaging tool for clinical practice? *Insights Imaging* 2012; **3**: 573-589 [PMID: 23093486 DOI: 10.1007/s13244-012-0196-6]

23 **Miles KA**, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: What do the measurements mean? *Cancer Imaging* 2013; **13**: 400-406 [PMID: 24061266 DOI: 10.1102/1470-7330.2013.9045]

24 **Hayano K**, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. *Dig Dis Sci* 2014; **59**: 1996-2003 [PMID: 24563237 DOI: 10.1007/s10620-014-3064-z]

25 **Hayano K**, Lee SH, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma. *Acad Radiol* 2014; **21**: 654-660 [PMID: 24703479 DOI: 10.1016/j.acra.2014.01.020]

26 **Ganeshan B**, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: Preliminary evidence of an association with tumour metabolism, stage, and survival. *Clin Radiol* 2012; **67**: 157-164 [PMID: 21943720 DOI: 10.1016/j.crad.2011.08.012]

27 **Yip C**, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaelidou A, Goh V. Primary esophageal cancer: Heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. *Radiology* 2014; **270**: 141-148 [PMID: 23985274 DOI: 10.1148/radiol.13122869]

28 **Tochigi T**, Shuto K, Kono T, Ohira G, Tohma T, Gunji H, Hayano K, Narushima K, Fujishiro T, Hanaoka T, Akutsu Y, Okazumi S, Matsubara H. Heterogeneity of Glucose Metabolism in Esophageal Cancer Measured by Fractal Analysis of Fluorodeoxyglucose Positron Emission Tomography Image: Correlation between Metabolic Heterogeneity and Survival. *Dig Surg* 2017; **34**: 186-191 [PMID: 27931038 DOI: 10.1159/000447751]

29 **Einstein A.** Investigations on the theory of the brownian movement. 1st ed. New York: Dover Publications, 1956

30 **Koh DM**, Padhani AR. Diffusion-weighted MRI: A new functional clinical technique for tumour imaging. *Br J Radiol* 2006; **79**: 633-635 [PMID: 16793851 DOI: 10.1259/bjr/29739265]

31 **Padhani AR**, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. *Neoplasia* 2009; **11**: 102-125 [PMID: 19186405 DOI: 10.1593/neo.81328]

32 **Cheng B**, Yu J. Predictive value of diffusion-weighted MR imaging in early response to chemoradiotherapy of esophageal cancer: A meta-analysis. *Dis Esophagus* 2019; **32**: pii: doy065 [PMID: 30010733 DOI: 10.1093/dote/doy065]

33 **Aoyagi T**, Shuto K, Okazumi S, Shimada H, Kazama T, Matsubara H. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. *Dig Surg* 2011; **28**: 252-257 [PMID: 21654173 DOI: 10.1159/000328770]

34 **Cong Q**, Li G, Wang Y, Zhang S, Zhang H. DW-MRI for esophageal squamous cell carcinoma, correlations between ADC values with histologic differentiation and VEGF expression: A retrospective study. *Oncol Lett* 2019; **17**: 2770-2776 [PMID: 30854051 DOI: 10.3892/ol.2019.9934]

35 **De Cobelli F**, Giganti F, Orsenigo E, Cellina M, Esposito A, Agostini G, Albarello L, Mazza E, Ambrosi A, Socci C, Staudacher C, Del Maschio A. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: Comparison with tumour regression grade at histology. *Eur Radiol* 2013; **23**: 2165-2174 [PMID: 23588582 DOI: 10.1007/s00330-013-2807-0]

36 **Imanishi S**, Shuto K, Aoyagi T, Kono T, Saito H, Matsubara H. Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma. *Dig Surg* 2013; **30**: 240-248 [PMID: 23880636 DOI: 10.1159/000351435]

37 **Wang L**, Liu L, Han C, Liu S, Tian H, Li Z, Ren X, Shi G, Wang Q, Wang G. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. *Radiother Oncol* 2016; **121**: 246-251 [PMID: 27838148 DOI: 10.1016/j.radonc.2016.10.021]

38 **Li QW**, Qiu B, Wang B, Wang DL, Yin SH, Yang H, Liu JL, Fu JH, Liu MZ, Xie CM, Liu H. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: A prospective study. *Dis Esophagus* 2018; **31** [PMID: 29036528 DOI: 10.1093/dote/dox121]

39 **van Rossum PS**, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. *Radiother Oncol* 2015; **115**: 163-170 [PMID: 26002307 DOI: 10.1016/j.radonc.2015.04.027]

40 **Fukunaga T**, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. *J Nucl Med* 1998; **39**: 1002-1007 [PMID: 9627333]

41 **Choi JY**, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, Choi Y, Choe YS, Kim BT. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: Prognostic implications. *J Nucl Med* 2004; **45**: 1843-1850 [PMID: 15534053]

42 **Choi JY**, Jang KT, Shim YM, Kim K, Ahn G, Lee KH, Choi Y, Choe YS, Kim BT. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. *Ann Surg Oncol* 2006; **13**: 1054-1062 [PMID: 16865594 DOI: 10.1245/ASO.2006.08.012]

43 **Kato H**, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. *Cancer* 2002; **94**: 921-928 [PMID: 11920459 DOI: 10.1002/cncr.10330]

44 **Kato H**, Takita J, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. *Anticancer Res* 2003; **23**: 3263-3272 [PMID: 12926062 DOI: 10.1111/j.1532-5415.2008.01796.x]

45 **Rizk N**, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, Rusch V. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. *Ann Thorac Surg* 2006; **81**: 1076-1081 [PMID: 16488726 DOI: 10.1016/j.athoracsur.2005.09.063]

46 **van Westreenen HL**, Plukker JT, Cobben DC, Verhoogt CJ, Groen H, Jager PL. Prognostic value of the standardized uptake value in esophageal cancer. *AJR Am J Roentgenol* 2005; **185**: 436-440 [PMID: 16037517 DOI: 10.2214/ajr.185.2.01850436]

47 **Omloo JM**, Sloof GW, Boellaard R, Hoekstra OS, Jager PL, van Dullemen HM, Fockens P, Plukker JT, van Lanschot JJ. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. *Endoscopy* 2008; **40**: 464-471 [PMID: 18543134 DOI: 10.1055/s-2008-1077302]

48 **Omloo JM**, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: A review. *Ann Surg Oncol* 2011; **18**: 3338-3352 [PMID: 21537872 DOI: 10.1245/s10434-011-1732-1]

49 **Chatterton BE**, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, Wong D, Ramshaw JE, Scott AM. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: Results of a multicentre prospective study. *Eur J Nucl Med Mol Imaging* 2009; **36**: 354-361 [PMID: 18931839 DOI: 10.1007/s00259-008-0959-y]

50 **Hong D**, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. *Cancer* 2005; **104**: 1620-1626 [PMID: 16118804 DOI: 10.1002/cncr.21356]

51 **Swisher SG**, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. *Ann Thorac Surg* 2004; **78**: 1152-60; discussion 1152-60 [PMID: 15464463 DOI: 10.1016/j.athoracsur.2004.04.046]

52 **Higuchi I**, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. *J Thorac Cardiovasc Surg* 2008; **136**: 205-212, 212.e1-212.e3 [PMID: 18603077 DOI: 10.1016/j.jtcvs.2008.02.016]

53 **Lordick F**, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. *Lancet Oncol* 2007; **8**: 797-805 [PMID: 17693134 DOI: 10.1016/S1470-2045(07)70244-9]

54 **Westerterp M**, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, Boellaard R, Vervenne WL, ten Kate FJ, van Lanschot JJ. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. *Int J Hyperthermia* 2006; **22**: 149-160 [PMID: 16754598 DOI: 10.1080/02656730500513523]

55 **Ott K**, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. *J Clin Oncol* 2006; **24**: 4692-4698 [PMID: 16966684 DOI: 10.1200/JCO.2006.06.7801]

56 **Port JL**, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, Mazumdar M, Altorki NK. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. *Ann Thorac Surg* 2007; **84**: 393-400; discussion 400 [PMID: 17643605 DOI: 10.1016/j.athoracsur.2007.03.094]

57 **Weber WA**, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. *J Clin Oncol* 2001; **19**: 3058-3065 [PMID: 11408502 DOI: 10.1200/JCO.2001.19.12.3058]

58 **Wieder HA**, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. *J Clin Oncol* 2004; **22**: 900-908 [PMID: 14990646 DOI: 10.1200/JCO.2004.07.122]

59 **Wieder HA**, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. *Eur J Nucl Med Mol Imaging* 2007; **34**: 1925-1932 [PMID: 17680242 DOI: 10.1007/s00259-007-0521-3]

**P-Reviewer:** Bagheri Lankarani K, Kakaei F, Liu DL **S-Editor:** Yan JP

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** Japan  
**Peer-review report classification**  
**Grade A (Excellent):** 0  
**Grade B (Very good):** B, B  
**Grade C (Good):** C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0

**Table 1 Summary of reports on computed tomography or magnetic resonance perfusion in esophageal cancer**


BF: Blood flow; pCR: Pathological complete response; CRT: Chemoradiation therapy; OS: Overall survival; CT: Computed tomography.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Year** | **Patients** | **Biomarker candidate** | **Prediction of treatment outcome** |
| Hayano *et al*[14] | 2007 | 31 | Baseline BF (CT perfusion) | High baseline BF associated with good response and OS after CRT (31) |
| Makari et al[15] | 2007 | 46 | Baseline BF (CT perfusion) | High baseline BF associated with good response and OS after chemotherapy (36) and CRT (10) |
| Djuric-Stefanovic *et al*[17] | 2015 | 40 | Post-therapeutic BF (CT perfusion) | Post-therapeutic BF < 30 mL/min/100 g can predict pCR with 100% of sensitivity and specificity |
| Lei *et al*[13] | 2015 | 25 | Baseline Ktrans (MR perfusion) | Ktrans was significantly different between CR and non-CR after CRT |
| Sun *et al*[12] | 2018 | 59 | Change of Ktrans (MR perfusion) | Change in Ktrans was the best parameter to assess treatment response |


**Table 2 Summary of reports on diffusion-weighted imaging in esophageal cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Year** | **Patients** | **Biomarker candidate** | **Prediction of treatment outcome** |
| Aoyagi *et al*[33] | 2011 | 80 | Baseline ADC | High baseline ADC associated with favorable survival after CRT |
| Imanishi *et al*[36] | 2013 | 27 | Early change of ADC, post-CRT ADC | Increase of ADC/high post-CRT ADC associated with good response to CRT |
| De Cobelli *et al*[35] | 2013 | 32 | Baseline ADC | High baseline ADC associated with poor response to CRT |
| Van Rossum *et al*[39] | 2015 | 20 | Early change of ADC | Increase of ADC associated with good response to CRT |
| Wang *et al*[37] | 2016 | 38 | Early change of ADC, post-CRT ADC | Increase of ADC/high post-CRT ADC associated with good response to CRT |
| Li *et al*[38] | 2017 | 28 | Early change of ADC, post-CRT ADC | Increase of ADC/high post-CRT ADC associated with good response to CRT |
| Cong *et al*[34] | 2019 | 52 | Baseline ADC | High baseline ADC associated with good response to RT |


ADC: Apparent diffusion coefficient; CRT: Chemoradiation therapy; RT: Radiation therapy.

****


**Figure 1 Perfusion change of esophageal cancer during chemoradiation therapy.** A: Computed tomography (CT) image at baseline; B: CT image at post-chemoradiation therapy (CRT); C: Blood flow map by CT perfusion at baseline; D: Blood flow map at post-CRT. Baseline blood flow of this tumor was low, and this patient was diagnosed as no-responder. CRT: Chemoradiation therapy; CT: Computed tomography.

****

**Figure 2 Histogram analysis of diffusion-weighted imaging.** Histogram analysis is one of the texture analyses. This is the histogram analysis of apparent diffusion coefficient (ADC) map. Region of interest (ROI) for the tumor is drawn on ADC map, and distribution of pixels in the ROI is quantified as histogram parameters such as kurtosis and skewness. ADC: Apparent diffusion coefficient; ROI: Region of interest.

****

**Figure 3 Advanced esophageal squamous cell carcinoma in** **contrast enhanced computed tomography image and diffusion-weighted imaging at b = 1000.** A: Contrast enhanced computed tomography image; B: Diffusion-weighted imaging. The tumor showed conspicuous high signal intensity on high b-value diffusion-weighted imaging.

****

**Figure 4** **18F-fluorodeoxyglucose positron emission tomography image of esophageal cancer.** A: Axial image; B: Coronal image. Malignancies exhibit strongly enhanced energy consumption, resulting in increased 18F-fluorodeoxyglucose uptake.